JLE

European Journal of Dermatology

MENU

Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib Volume 26, numéro 5, September-October 2016

Illustrations


  • Figure 1

  • Figure 2

  • Figure 3

Tableaux

Auteurs
1 Family Medicine Department,
Nantes Medical School,
1 rue Gaston Veil
44035 Nantes,
2 CRCNA,
INSERM U892,
CNRS 6299,
9 Quai Moncousu,
44093 Nantes,
3 PIMESP-SEB,
Hôpital St Jacques,
85 rue St Jacques,
44093 Nantes,
4 Dermato-Cancerology Department,
CHU Hôtel-Dieu,
1 Place Alexis Ricordeau,
44093 Nantes,
5 Unité de Thérapie Cellulaire et Génique (UTCG),
CHU Hôtel-Dieu,
9 Quai Moncousu,
44093 Nantes,
France
* Reprints

Basal cell carcinoma (BCC) is the most common cancer worldwide, and its prevalence is increasing, accounting for 80% of non-melanoma skin cancers [1]. In the United States, BCC has an estimated annual prevalence of 0.1 to 0.5% [2] and 1.6 million new patients were treated in 2006 [3]. BCC is a heterogeneous group of tumours with multiple clinical presentations and histological pathologies [4]. Most of the time, BCC exhibits slow growth, limited soft tissues invasiveness [5], low regional or distant [...]